Published on December 4, 2009 at 2:35 AM
Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX) announced today that data from a recent clinical trial for Caldolor® (ibuprofen) Injection, an intravenous treatment for pain and fever, will be presented at the 44th American Society of Health-System Pharmacists (ASHP) Midyear Clinical Meeting in Las Vegas, Nevada, in December.
The new data will be displayed in a poster presentation on Monday, December 7, from 2:30 to 5:00 pm PST (board 3-157). The study, entitled "A Randomized, Double-Blind, Placebo-Controlled, Single Dose, Crossover Study of the Pharmacokinetics, Safety and Tolerability of Ibuprofen Injection in Healthy Adult Volunteers," will be presented by the principal author, Leo Pavliv, RPh, MBA.
This pharmacokinetic study evaluated a single dose of Caldolor administered over five to seven minutes as compared to a single dose of oral ibuprofen. Results from the trial demonstrate the effects of decreasing infusion time for Caldolor from the current package insert guideline of no less than 30 minutes to an infusion time of five to seven minutes.
SOURCE Cumberland Pharmaceuticals Inc.
0b8a77dd-2ac7-4d1f-918d-78b9d82e5ab9|0|.0
Posted in: Pharmaceutical News
Tags: Acetaminophen, Aspirin, Asthma, Blood Pressure, Gastroenterology, Heart Failure, Hospital, Hypersensitivity, Ibuprofen, Pharmacokinetics, Placebo, Ulcer, Urticaria